Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 le...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, I., Pouillart, P., Fridman, W. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968905/
https://www.ncbi.nlm.nih.gov/pubmed/8180022
_version_ 1782134842588135424
author Tartour, E.
Dorval, T.
Mosseri, V.
Deneux, L.
Mathiot, C.
Brailly, H.
Montero, F.
Joyeux, I.
Pouillart, P.
Fridman, W. H.
author_facet Tartour, E.
Dorval, T.
Mosseri, V.
Deneux, L.
Mathiot, C.
Brailly, H.
Montero, F.
Joyeux, I.
Pouillart, P.
Fridman, W. H.
author_sort Tartour, E.
collection PubMed
description Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.
format Text
id pubmed-1968905
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19689052009-09-10 Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Tartour, E. Dorval, T. Mosseri, V. Deneux, L. Mathiot, C. Brailly, H. Montero, F. Joyeux, I. Pouillart, P. Fridman, W. H. Br J Cancer Research Article Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed. Nature Publishing Group 1994-05 /pmc/articles/PMC1968905/ /pubmed/8180022 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Tartour, E.
Dorval, T.
Mosseri, V.
Deneux, L.
Mathiot, C.
Brailly, H.
Montero, F.
Joyeux, I.
Pouillart, P.
Fridman, W. H.
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title_full Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title_fullStr Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title_full_unstemmed Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title_short Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.
title_sort serum interleukin 6 and c-reactive protein levels correlate with resistance to il-2 therapy and poor survival in melanoma patients.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968905/
https://www.ncbi.nlm.nih.gov/pubmed/8180022
work_keys_str_mv AT tartoure seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT dorvalt seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT mosseriv seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT deneuxl seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT mathiotc seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT braillyh seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT monterof seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT joyeuxi seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT pouillartp seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients
AT fridmanwh seruminterleukin6andcreactiveproteinlevelscorrelatewithresistancetoil2therapyandpoorsurvivalinmelanomapatients

Ejemplares similares